Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Business research collaboration

Evotec and Plectonic Biotech Research Collaboration

Analysis based on 9 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026

Sentiment
15
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The collaboration is a positive development for Evotec, potentially strengthening its oncology pipeline and validating its BiTco platform, which could enhance its attractiveness to partners and investors. For Plectonic, the partnership with a major player like Evotec provides validation and resources to advance its LOGIBODY technology, though financial terms were not disclosed and the impact is likely modest in the near term.

Biotechnology Pharmaceutical

On September 2, 2026, Evotec and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration combines Plectonic's programmable LOGIBODY technology, which uses logic-gated DNA-protein therapeutics to recognize tumors via a predefined multi-antigen signature before engaging T cells, with Evotec's proprietary BiTco platform, based on a non-blocking CD2 antibody that provides costimulatory signals to enhance T cell activity and persistence. The goal is to improve the precision and potency of T-cell-engaging therapies in solid tumors, which represent about 90% of all cancers. The collaboration will generate preclinical proof-of-concept data. Evotec's Chief Scientific Officer, Cord Dohrmann, and Plectonic's CEO, Klaus Wagenbauer, both expressed optimism about the potential of combining their technologies to address challenges in tumor selectivity and safety.

90 Evotec entered collaboration Plectonic Biotech
90 Plectonic Biotech entered collaboration Evotec
stock
Evotec is a key participant, contributing its BiTco platform to the collaboration. The deal may enhance its oncology pipeline and validate its technology, potentially supporting its stock price.
Importance 100.0 Sentiment 20.0
priv
Plectonic is a key participant, providing its LOGIBODY technology. The collaboration with Evotec validates its platform and provides resources to advance its pipeline, though it is a private company.
Importance 100.0 Sentiment 30.0
per
As Evotec's Chief Scientific Officer, Cord Dohrmann is a spokesperson for the collaboration, but the event does not directly affect him personally.
Importance 20.0 Sentiment 0.0
per
As CEO and founder of Plectonic, Klaus Wagenbauer is a spokesperson for the collaboration, but the event does not directly affect him personally.
Importance 20.0 Sentiment 0.0
index
SDAX is the index in which Evotec is listed. The collaboration is a minor positive for Evotec, but the index movement is influenced by many factors; the event has negligible impact on the index.
Importance 5.0 Sentiment -10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.